French researchers call to arms to prevent science reform


Paris – French researchers have begun massive protests to prevent the reform of the national French research system. Valérie Pecresse, the Minister of Research, had announced plans to restructure it.
According to the government’s plans, the country’s largest national research organization, the CNRS (Centre National de Recherche Scientifique), which employs more than 11,000 scientists, is to be split up into six institutes (mathematics, physics, chemistry, engineering, human sciences, ecology and biodiversity). All other research topics that have been covered by the CNRS up to now are to be dropped. Natural sciences such as biotechnology or pharmacy are to be attached to associations such as INSERM (Institut National de la Santé et de la Recherche Médicale). Because INSERM is traditionally linked to applied research, however, the scientists fear that basic research will lose ground in France. The directors of the newly established six research bodies are not to be elected by colleagues, but instead nominated by the government. Anxiety in the research community is high that the government or private sector could begin acting as sponsors for specific research. Under the new plan, public funding is only to be given to finance special, short-term projects.

Researchers fear loss of basic


The CNRS is a focus of national pride in France. It employs more than 32,000 people, including around 11,600 researchers and 14,400 engineers, technicians and administrative personnel. Its budget was EUR3.3 billion in 2008, around EUR588 million of which came from its own resources, mainly from licensing. However, according to a ranking by the Chinese Jiao Tong University (Shanghai) the structure of the CNRS is not compatible with international standards. Valérie Pecresse is trying to change that, and has reminded the protestors of two succesful predecessors. In the mid-80s, the CNRS transfer of the areas of nuclear physics and space into separate institutes was a resounding success, and went off without a hitch.



Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...



Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...



Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...



Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...



Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...



Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...



Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...



Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...



Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...



Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues